2024

1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

   Annals of Hematology

2. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

   Blood

3. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

   Haematologica, Vol. 109, Núm. 6, pp. 1909-1917